Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2025-12-25 @ 1:23 AM
NCT ID:
NCT00813293
Eligibility Criteria:
Inclusion Criteria:
* Confirmed hepatocellular cancer (HCC) by pathology or by NCCN imaging guidelines
* All HCC stages are allowed. May be a liver transplant candidate.
* At least one tumor (index tumor) accurately measured as 3.5-7cm in diameter (long and short axis diameter to be recorded, but only one needs to meet this criteria) on baseline imaging.
* No prior therapy for the index tumor
* No prior systemic treatment for HCC within 4 weeks and no prior anti-VEGF therapy within 8 weeks of study entry.
* Life expectancy \> 8 weeks.
* ECOG \>=0 or 1
* RFA clinically indicated for index tumor.
* Acceptable overall RFA and anesthesia risk.
* Adequate bone marrow, liver and renal function: Hemoglobin \>9.0 g/dl; Absolute neutrophil count (ANC)\>1,500/mm3; Platelet count correctable to \>50,000/mm3; compensated liver function (Child-Turcotte-Pugh A, B7 or B8); Creatinine \<1.5 times ULN; INR correctable to \<1.5.
* Ability to take oral medication and no evidence of impaired absorption.
Exclusion Criteria
* Urgent treatment of the index tumor anticipated.
* Participants who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Participants currently receiving any other study agents.
* Known brain metastases
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib.
* Participants receiving medications or substances that are inducers of CYP3A4 (rifampicin, St. John's wort, phenytoin, carbamazepine, phenobarbital and dexamethasone) or that are metabolized/eliminated by predominantly UGT1A1 pathway or by CYP2B6 and CYP2C8.
* Decompensated liver disease
* Uncontrolled hypertension
* Thrombolic or embolic events within the past 6 months.
* Hemorrhage/bleeding event within 4 weeks
* Serious non-healing wound, ulcer, or bone fracture.
* Evidence of severe or uncorrectable bleeding diathesis or coagulopathy
* Major surgery, open biopsy or significant traumatic injury within 4 weeks of study entry.
* Contraindication to or inability to undergo the RFA procedure,
* Contraindication to or inability to undergo imaging with MRI
* Uncontrolled intercurrent illness
* Individuals with a history of a different malignancy unless disease-free for at least 5 years and are deemed by the Investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
* HIV-positive individuals on combination antiretroviral therapy
For additional inclusion/exclusion criteria details contact Study Site.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00813293
Study Brief:
Protocol Section:
NCT00813293